Thread by @MPishvaian

📢In preparation for #ASCO22, I wanted to present my list for the #PancreaticCancer abstracts to👀for @ASCO

Again,🙏note - I went through a LOT of abstracts, and I definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀

#ASCO22 #PancreaticCancer
🤔Is more better❓
✅Dr. Carrato🧑‍🏫a Rand trial
👉Gem-nab-pac➡️FOLFOX (sequenced Q6 wks)
vs.
👉Standard Gem-nab-pac
➡️mOS was 3.5mos⬆️with sequenced Tx
➡️Even though more standard pts got 2nd line Tx
🤯Really❓
🤔Interesting
🔎GI Can Oral Abst 4022

#ASCO22 #PancreaticCancer
🤔Is more better❓
✅Similarly, Dr. Portalesa🧑‍🏫a Rand Ph2 "Trial in Progress" comparing:
👉Sequential gem-nab-pac➡️FFX
vs.
👉Standard FFX alone
➡️Primary objective is OS
🤔But really, what will be critical will be the OS
🔎Abst TPS4190, Poster 160a

#ASCO22 #PancreaticCancer
🔥Promising new💊

✅Dr. Van Custem🧑‍🏫a Ph1/2 trial of an anti-IL1RAP mAb, nadunolimab + gem-nab-pac
➡️73 efficacy assessable pts
➡️mOS – 13.2 mos
➡️But ORR only 33%
🔎Poster🗣️Session Abst 4141, Poster 11

#ASCO22 #PancreaticCancer
🔥Promising new💊
📣Claudin 18.2 hits PDAC too

✅Dr. Botta🧑‍🏫a Ph1b trial of CT041 a Claudin 18.2-specific CAR-T cell Tx
➡️Out of 8 evaluable pts there was 1 CR, 2PRs – all gastric
➡️2/5 with a minor response in PDAC
🔎Abst 2528, Poster 193

#ASCO22 #PancreaticCancer
🔥Promising new💊

✅Dr. Musher 🧑‍🏫the Ph1/2 trial of gem-nab-pac➕LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus
➡️LOAd703💉intratumorally
➡️Induces anti-tumor cytotox T-cell response
➡️18 eval pts injected, ORR was 55%
🔎Abst 4138, Poster 124

#ASCO22 #PancreaticCancer
🔥Adjuvant vaccines are promising

✅Dr. Balachandran🧑‍🏫a Ph1 trial of an individualized neoAg adjuvant vaccine
➡️If there was a IFN-producing T-cell response, then the RFS was not reached
🤔Early – but hopeful?
🔎Poster🗣️Session Abst 2516, Poster 172

#ASCO22 #PancreaticCancer
🛑But R maint vaccines promising❓
✅Dr. Hilmi🧑‍🏫a Ph2 trial of OSE2101 after induction FFX for mPDAC
➡️OSE2101=a multiple neoepitope vaccine for HLA-A2➕Pts
🤔But wait – the OS is lower with the vaccine
👁️Need to look closer
🔎Abst 4148, Poster 133

#ASCO22 #PancreaticCancer
🔥Keep an👁️out for 2 promising studies:

✅Dr. Qin🧑‍🏫a Ph3 trial of gem +/- nimotuzumab in KRAS WT LAPC
🔎GI CSS LBAA4011

✅Dr. Neuzillet🧑‍🏫a Rand trial of Physical Activity (APA) in PDAC
➡️APA improved QOL
📣OS and PFS coming
🔎GI Ca Oral Abst 4007

#ASCO22 #PancreaticCancer
☹️Finally, the "negative" trials

✅Dr. Fietkau🧑‍🏫a Ph3 trial of chemo +/-☢️in LAPC
➡️R0 resection 10% with☢️
➡️BUT OS was 🟰
🤔Maybe even a reasonable endpoint like R0 resection doesn’t matter in PDAC❓
🔎GI Ca Oral Abst 4008

📢The🗣️over☢️roars on‼️

#ASCO22 #PancreaticCancer
☹️Finally, the "negative" trials

✅Dr. Philip🧑‍🏫the Ph3 trial of FFX +/- CPI-613
➡️CPI-613🚫the TCA cycle
👉mOS for FFX=11.1 mos
👉mOS for CPI-613=11.7 mos
🤔Did the control arm actually UNDERperform❓
🔎Poster🗣️Session Abst 4023, Poster 10